Loading…
Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim
In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the ant...
Saved in:
Published in: | Breast cancer research : BCR 2012-03, Vol.14 (2), p.R52-R52, Article R52 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83 |
---|---|
cites | cdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83 |
container_end_page | R52 |
container_issue | 2 |
container_start_page | R52 |
container_title | Breast cancer research : BCR |
container_volume | 14 |
creator | Periyasamy-Thandavan, Sudharsan Takhar, Suchreet Singer, Adam Dohn, Michael Robert Jackson, William Hutch Welborn, April Eve LeRoith, Derek Marrero, Mario Thangaraju, Muthusamy Huang, Shuang Schoenlein, Patricia Veronica |
description | In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1.
IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors.
IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells.
his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effe |
doi_str_mv | 10.1186/bcr3153 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3446386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478424654</galeid><sourcerecordid>A478424654</sourcerecordid><originalsourceid>FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</originalsourceid><addsrcrecordid>eNp1ktGK1DAUhoso7rqKbyABLxSka9KmbcYLYXcZdxdXBFHwLiTpSSfaJjVJlXks39B0Oy4zoOQiOSf__-VwcrLsKcGnhLD6tVS-JFV5LzsmtK7yihZf7--dj7JHIXzDmDSsYg-zo6KgxYquyHH2-9qGqTc27813QJ13v-IGaaGi84ggESPYSUQISNhoIETvOrB5itrbzDjHISa_se2kIGVHN0YXTEDGovWnV0h6ECEiJawCjxT0fUByiz6s3xPkoZt6EY2zyGkUN4DOr8rc2X6LEjlfWNGoOYqQgOdmeJw90KIP8GS3n2Rf3q0_X1zlNx8vry_ObnJJWRNzRXGtCBECQ1UVZdsqSTFo0TQEQ8sUoZKJlrZEMtZotdKKyJJWDDdSVLpl5Un2duGOkxygVWCjFz0fvRmE33InDD-8sWbDO_eTl5TWJasT4M0CkMb9B3B4o9zAdx-ZzC93r3v3Y0ot5oMJc_OEBTcFTjAlZUEJxkn6fJF2ogdurHaJpmY5P6MNo0WaAppUp_9QpdXCYJSzoE3KHxheLAblXQge9F3lBPN56PZqfbbfqTvd3ykr_wBRBtds</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1041324100</pqid></control><display><type>article</type><title>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</title><source>PubMed Central</source><creator>Periyasamy-Thandavan, Sudharsan ; Takhar, Suchreet ; Singer, Adam ; Dohn, Michael Robert ; Jackson, William Hutch ; Welborn, April Eve ; LeRoith, Derek ; Marrero, Mario ; Thangaraju, Muthusamy ; Huang, Shuang ; Schoenlein, Patricia Veronica</creator><creatorcontrib>Periyasamy-Thandavan, Sudharsan ; Takhar, Suchreet ; Singer, Adam ; Dohn, Michael Robert ; Jackson, William Hutch ; Welborn, April Eve ; LeRoith, Derek ; Marrero, Mario ; Thangaraju, Muthusamy ; Huang, Shuang ; Schoenlein, Patricia Veronica</creatorcontrib><description>In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1.
IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors.
IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells.
his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.</description><identifier>ISSN: 1465-542X</identifier><identifier>ISSN: 1465-5411</identifier><identifier>EISSN: 1465-542X</identifier><identifier>DOI: 10.1186/bcr3153</identifier><identifier>PMID: 22429491</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Apoptosis ; Apoptosis - drug effects ; Apoptosis Regulatory Proteins - metabolism ; Bcl-2-Like Protein 11 ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer cells ; Cancer treatment ; Care and treatment ; Cell Line, Tumor ; Enzyme Inhibitors - pharmacology ; Enzymes ; Estrogen Antagonists - pharmacology ; Estrogen Receptor Modulators - pharmacology ; Estrogens ; Female ; Health aspects ; Hormone Antagonists - pharmacology ; Humans ; Insulin-Like Growth Factor I - metabolism ; Insulin-Like Growth Factor I - pharmacology ; Keratin ; MAP Kinase Kinase 1 - antagonists & inhibitors ; MAP Kinase Kinase 1 - genetics ; MAP Kinase Kinase 1 - metabolism ; Membrane Proteins - metabolism ; Mifepristone - pharmacology ; Monosaccharides ; Oxidative Stress - drug effects ; Phosphorylation - drug effects ; Proto-Oncogene Proteins - metabolism ; Reactive Oxygen Species - metabolism ; Receptors, Estrogen - metabolism ; Tamoxifen - analogs & derivatives ; Tamoxifen - pharmacology</subject><ispartof>Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R52-R52, Article R52</ispartof><rights>COPYRIGHT 2012 BioMed Central Ltd.</rights><rights>Copyright ©2012 Schoenlein et al.; licensee BioMed Central Ltd. 2012 Schoenlein et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</citedby><cites>FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446386/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446386/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22429491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Periyasamy-Thandavan, Sudharsan</creatorcontrib><creatorcontrib>Takhar, Suchreet</creatorcontrib><creatorcontrib>Singer, Adam</creatorcontrib><creatorcontrib>Dohn, Michael Robert</creatorcontrib><creatorcontrib>Jackson, William Hutch</creatorcontrib><creatorcontrib>Welborn, April Eve</creatorcontrib><creatorcontrib>LeRoith, Derek</creatorcontrib><creatorcontrib>Marrero, Mario</creatorcontrib><creatorcontrib>Thangaraju, Muthusamy</creatorcontrib><creatorcontrib>Huang, Shuang</creatorcontrib><creatorcontrib>Schoenlein, Patricia Veronica</creatorcontrib><title>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</title><title>Breast cancer research : BCR</title><addtitle>Breast Cancer Res</addtitle><description>In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1.
IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors.
IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells.
his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.</description><subject>Analysis</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis Regulatory Proteins - metabolism</subject><subject>Bcl-2-Like Protein 11</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer cells</subject><subject>Cancer treatment</subject><subject>Care and treatment</subject><subject>Cell Line, Tumor</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzymes</subject><subject>Estrogen Antagonists - pharmacology</subject><subject>Estrogen Receptor Modulators - pharmacology</subject><subject>Estrogens</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hormone Antagonists - pharmacology</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Insulin-Like Growth Factor I - pharmacology</subject><subject>Keratin</subject><subject>MAP Kinase Kinase 1 - antagonists & inhibitors</subject><subject>MAP Kinase Kinase 1 - genetics</subject><subject>MAP Kinase Kinase 1 - metabolism</subject><subject>Membrane Proteins - metabolism</subject><subject>Mifepristone - pharmacology</subject><subject>Monosaccharides</subject><subject>Oxidative Stress - drug effects</subject><subject>Phosphorylation - drug effects</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Tamoxifen - analogs & derivatives</subject><subject>Tamoxifen - pharmacology</subject><issn>1465-542X</issn><issn>1465-5411</issn><issn>1465-542X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1ktGK1DAUhoso7rqKbyABLxSka9KmbcYLYXcZdxdXBFHwLiTpSSfaJjVJlXks39B0Oy4zoOQiOSf__-VwcrLsKcGnhLD6tVS-JFV5LzsmtK7yihZf7--dj7JHIXzDmDSsYg-zo6KgxYquyHH2-9qGqTc27813QJ13v-IGaaGi84ggESPYSUQISNhoIETvOrB5itrbzDjHISa_se2kIGVHN0YXTEDGovWnV0h6ECEiJawCjxT0fUByiz6s3xPkoZt6EY2zyGkUN4DOr8rc2X6LEjlfWNGoOYqQgOdmeJw90KIP8GS3n2Rf3q0_X1zlNx8vry_ObnJJWRNzRXGtCBECQ1UVZdsqSTFo0TQEQ8sUoZKJlrZEMtZotdKKyJJWDDdSVLpl5Un2duGOkxygVWCjFz0fvRmE33InDD-8sWbDO_eTl5TWJasT4M0CkMb9B3B4o9zAdx-ZzC93r3v3Y0ot5oMJc_OEBTcFTjAlZUEJxkn6fJF2ogdurHaJpmY5P6MNo0WaAppUp_9QpdXCYJSzoE3KHxheLAblXQge9F3lBPN56PZqfbbfqTvd3ykr_wBRBtds</recordid><startdate>20120319</startdate><enddate>20120319</enddate><creator>Periyasamy-Thandavan, Sudharsan</creator><creator>Takhar, Suchreet</creator><creator>Singer, Adam</creator><creator>Dohn, Michael Robert</creator><creator>Jackson, William Hutch</creator><creator>Welborn, April Eve</creator><creator>LeRoith, Derek</creator><creator>Marrero, Mario</creator><creator>Thangaraju, Muthusamy</creator><creator>Huang, Shuang</creator><creator>Schoenlein, Patricia Veronica</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120319</creationdate><title>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</title><author>Periyasamy-Thandavan, Sudharsan ; Takhar, Suchreet ; Singer, Adam ; Dohn, Michael Robert ; Jackson, William Hutch ; Welborn, April Eve ; LeRoith, Derek ; Marrero, Mario ; Thangaraju, Muthusamy ; Huang, Shuang ; Schoenlein, Patricia Veronica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Analysis</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis Regulatory Proteins - metabolism</topic><topic>Bcl-2-Like Protein 11</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer cells</topic><topic>Cancer treatment</topic><topic>Care and treatment</topic><topic>Cell Line, Tumor</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzymes</topic><topic>Estrogen Antagonists - pharmacology</topic><topic>Estrogen Receptor Modulators - pharmacology</topic><topic>Estrogens</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hormone Antagonists - pharmacology</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Insulin-Like Growth Factor I - pharmacology</topic><topic>Keratin</topic><topic>MAP Kinase Kinase 1 - antagonists & inhibitors</topic><topic>MAP Kinase Kinase 1 - genetics</topic><topic>MAP Kinase Kinase 1 - metabolism</topic><topic>Membrane Proteins - metabolism</topic><topic>Mifepristone - pharmacology</topic><topic>Monosaccharides</topic><topic>Oxidative Stress - drug effects</topic><topic>Phosphorylation - drug effects</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Tamoxifen - analogs & derivatives</topic><topic>Tamoxifen - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Periyasamy-Thandavan, Sudharsan</creatorcontrib><creatorcontrib>Takhar, Suchreet</creatorcontrib><creatorcontrib>Singer, Adam</creatorcontrib><creatorcontrib>Dohn, Michael Robert</creatorcontrib><creatorcontrib>Jackson, William Hutch</creatorcontrib><creatorcontrib>Welborn, April Eve</creatorcontrib><creatorcontrib>LeRoith, Derek</creatorcontrib><creatorcontrib>Marrero, Mario</creatorcontrib><creatorcontrib>Thangaraju, Muthusamy</creatorcontrib><creatorcontrib>Huang, Shuang</creatorcontrib><creatorcontrib>Schoenlein, Patricia Veronica</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research : BCR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Periyasamy-Thandavan, Sudharsan</au><au>Takhar, Suchreet</au><au>Singer, Adam</au><au>Dohn, Michael Robert</au><au>Jackson, William Hutch</au><au>Welborn, April Eve</au><au>LeRoith, Derek</au><au>Marrero, Mario</au><au>Thangaraju, Muthusamy</au><au>Huang, Shuang</au><au>Schoenlein, Patricia Veronica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim</atitle><jtitle>Breast cancer research : BCR</jtitle><addtitle>Breast Cancer Res</addtitle><date>2012-03-19</date><risdate>2012</risdate><volume>14</volume><issue>2</issue><spage>R52</spage><epage>R52</epage><pages>R52-R52</pages><artnum>R52</artnum><issn>1465-542X</issn><issn>1465-5411</issn><eissn>1465-542X</eissn><abstract>In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells, we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF). Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound insulinIGF-1.
IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative cDNA were used to identify key IGF-1 downstream prosurvival effectors.
IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1 expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells.
his study provides strong support for the use of MEK1 inhibitors in combination with hormonal therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells. We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of IGF-1, which have been correlated to a poor prognosis.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>22429491</pmid><doi>10.1186/bcr3153</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1465-542X |
ispartof | Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R52-R52, Article R52 |
issn | 1465-542X 1465-5411 1465-542X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3446386 |
source | PubMed Central |
subjects | Analysis Apoptosis Apoptosis - drug effects Apoptosis Regulatory Proteins - metabolism Bcl-2-Like Protein 11 Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer cells Cancer treatment Care and treatment Cell Line, Tumor Enzyme Inhibitors - pharmacology Enzymes Estrogen Antagonists - pharmacology Estrogen Receptor Modulators - pharmacology Estrogens Female Health aspects Hormone Antagonists - pharmacology Humans Insulin-Like Growth Factor I - metabolism Insulin-Like Growth Factor I - pharmacology Keratin MAP Kinase Kinase 1 - antagonists & inhibitors MAP Kinase Kinase 1 - genetics MAP Kinase Kinase 1 - metabolism Membrane Proteins - metabolism Mifepristone - pharmacology Monosaccharides Oxidative Stress - drug effects Phosphorylation - drug effects Proto-Oncogene Proteins - metabolism Reactive Oxygen Species - metabolism Receptors, Estrogen - metabolism Tamoxifen - analogs & derivatives Tamoxifen - pharmacology |
title | Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin-like%20growth%20factor%201%20attenuates%20antiestrogen-%20and%20antiprogestin-induced%20apoptosis%20in%20ER+%20breast%20cancer%20cells%20by%20MEK1%20regulation%20of%20the%20BH3-only%20pro-apoptotic%20protein%20Bim&rft.jtitle=Breast%20cancer%20research%20:%20BCR&rft.au=Periyasamy-Thandavan,%20Sudharsan&rft.date=2012-03-19&rft.volume=14&rft.issue=2&rft.spage=R52&rft.epage=R52&rft.pages=R52-R52&rft.artnum=R52&rft.issn=1465-542X&rft.eissn=1465-542X&rft_id=info:doi/10.1186/bcr3153&rft_dat=%3Cgale_pubme%3EA478424654%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b487t-c406c11aa0e5523ddcb40efa7710ed8c14b8ad4d1b887fc9fc1b345807ba5fd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1041324100&rft_id=info:pmid/22429491&rft_galeid=A478424654&rfr_iscdi=true |